To establish requirements for purchasing certain generic drugs from manufacturers who produce the drug domestically.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The AMERICAN DRUGS Act requires federal healthcare programs (Medicare, Medicaid, CHIP, VA, and DoD) to buy only domestically-manufactured generic drugs when at least two domestic options are available. The FDA must notify these agencies when domestic alternatives exist or when supply issues arise.
Who Benefits and How
Domestic pharmaceutical manufacturers benefit significantly by gaining preferential access to the large federal healthcare market. U.S.-based generic drug producers will face reduced competition from foreign manufacturers for government contracts. American pharmaceutical workers benefit from increased domestic production demand.
Who Bears the Burden and How
Foreign generic drug manufacturers (particularly in India and China) lose access to federal healthcare program sales when domestic alternatives exist. Federal healthcare programs may face higher drug costs if domestic generics are priced higher than foreign alternatives. Taxpayers may bear increased costs for government healthcare programs.
Key Provisions
- Medicare Part B and Part D can only cover domestically-manufactured generic drugs after January 1, 2025
- Medicaid and CHIP must exclude foreign-made generics when domestic alternatives exist
- VA and DoD procurement limited to domestically-manufactured generics
- FDA must expedite review of applications for domestic generic drugs with limited domestic competition
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Establishes Buy American requirements for generic drug procurement by federal healthcare programs including Medicare, Medicaid, CHIP, VA, and DoD
Key Policy Areas
Healthcare, Pharmaceuticals, Government Procurement, Domestic Manufacturing
Primary Purpose
Establishes Buy American requirements for generic drug procurement by federal healthcare programs including Medicare, Medicaid, CHIP, VA, and DoD
Policy Domains
Whole Bill - AMERICAN DRUGS Act
Identified Gains
Contextual inference, no direct clause citation- Domestic generic drug manufacturers
- U.S. pharmaceutical workers
- American generic drug producers
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Foreign generic drug manufacturers
- Federal healthcare programs
- Taxpayers
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMr. Scott of Florida introduced the following bill; which was …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Domestic generic drug manufacturers, Domestic generic drug manufacturers seeking FDA approval, Foreign generic drug manufacturers
Positive-direction: Domestic generic drug manufacturers, Domestic generic drug manufacturers seeking FDA approval
Negative-direction: Foreign generic drug manufacturers
Department of Defense, Department of Veterans Affairs, FDA (Food and Drug Administration)
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services (primary); Secretary of Defense (DoD sections); Secretary of Veterans Affairs (VA sections)
- "the_commissioner"
- → Commissioner of Food and Drugs
- "the_administrator"
- → Administrator of the Centers for Medicare & Medicaid Services
Note: 'The Secretary' refers to different Secretaries depending on context: HHS (FDA provisions), Defense (DoD provisions), or Veterans Affairs (VA provisions)
Key Definitions
Terms defined in this bill
A drug approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act for which there is at least one establishment registered under section 510(b)(1) engaged in manufacture of the finished dosage form in the United States
A covered outpatient drug that is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and is not a generic drug manufactured domestically
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology